medigraphic.com
ISSN 1027-2852 (Electronic)
ISSN 0864-4551 (Print)

2020, Number 4

<< Back

Biotecnol Apl 2020; 37 (4)

The role of Pharmacometrics in the development of Cuban Biotechnology products

Rodríguez VL, Reynaldo FG, Fernández-Sánchez EM, Ramos SM, Amaro D, Menéndez R, Colom H, Mangas SV, Castañeda G, Duconge J, Jiménez VB, de Castro SN, Viada C, Solazábal J, Bécquer MA

Language: English
References: 28
Page: 4501-4507
PDF size: 392.78 Kb.


ABSTRACT

Pharmacometrics is a vibrant scientific discipline that involves a cycle of excellence: integration, innovation and impact. This work was aimed to assess different pharmacometric approaches in three Cuban biotechnological products. A population pharmacokinetic analysis of nimotuzumab was performed in patients with stage III breast cancer with different doses of it, in combination with doxorubicin and cyclophosphamide. The pharmacokinetic/pharmacodynamic (PK/PD) characterization of Pegylated Recombinant Human Erythropoietin (rHuEPO) branched 32 kDa-PEG-rHuEPO and 40 kDa- PEG-rHuEPO was conducted and compared with reference products (ior®EPOCIM and MIRCERA®) in New Zealand rabbits. Data were analyzed using the nonlinear mixed–effect approach (NONMEM®). The best model for nimotuzumab was the Quasi Steady State approximation of the full Target Mediated Drug Disposition model that best described the linear and nonlinear PK. The recommended optimal biological dose ranged between 200-400mg/week. On the other hand, a cell transit semi-mechanistic PK/PD model for characterizing rHuEPO profiles was obtained. The development of new branched PEG-chain formulations of rHuEPO improves its PK and PD properties, compared to those of commercially available formulations (i.e., ior®EPOCIM and MIRCERA®). Due to its integrative nature and predictive value, population modeling was very useful in the optimal characterization of the pharmacokinetic and pharmacodynamic properties of these three Cuban biotech drug products. It had a significant impact on decision-making by both the national regulatory agency and the local biopharmaceutical industry as to their research and development plans, as well as the subsequent marketing strategies for these new products, with substantial economic and time saving benefits. This work received the Annual Award of the Cuban Academy of Sciences for the year 2019.


REFERENCES

  1. Williams P, Ette E, editors. Pharmacometrics: impacting drug development and Pharmacotherapy Hoboken, New Jersey: John Wiley and Sns, Inc.; 2007.

  2. Pfiste M, D’Argenio aD. The emerging scientific Discipline of pharmacometrics. J Clin Pharmacol. 2010;50:6S.

  3. Owen JS, Fiedler-Kelly J. Introduction to population pharmacokinetic/pharmacodynamic analysis with nonlinear mixed effects models: John Wiley & Sons; 2014.

  4. Advanced breast cancer with monoclonal antibody hR3 in combination with doxorubicin and cyclophosphamide. Phase I. [Internet]. 2008 [cited 2014 /9/18]. Available from: http://rpcec.sld.cu/trials/ RPCEC00000057-En

  5. Commission E. Caring for animals aiming for better science of the European Union. In: Directive 2010/63/EU on Protection of Animals Used for Scientific Purposes 2010.

  6. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C. Guidelines for reporting experiments involving animals: the ARRIVE guidelines. British J Pharmacol. 2010;160(7):1573-6.

  7. Bain BJ, Bates I, Laffan MA. Dacie and Lewis Practical Haematology: Elsevier Health Sciences; 2017.

  8. Bauer R. Introduction to NONMEM 7.3. 0. NONMEM users guide. 2015.

  9. Jonsson EN, Karlsson MO. Xpose--an SPLUS based population pharmacokinetic/ pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51-64.

  10. Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit- a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241-57.

  11. Team RC. R: A language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria. 2013.

  12. Pharsight. Phoenix 64 WinNonlin software version 6.3. St. Louis Missouri 2005-2012.

  13. Dirks NL, Nolting A, Kovar A, Meibohm B. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J Clin Pharmacol. 2008;48:267-78.

  14. Kuester K, Kovar A, Lüpfert C, Brockhaus B, Kloft C. Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations. Clin Pharmacokinet. 2009;48(7):477-87.

  15. Fornier MN, Seidman AD, Schwartz MK, Ghani F, Thiel R, Norton L, et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2005;16:234-9.

  16. Crombet T, Casaco A, Iznaga N. h-R3. Drugs of the Future. 2003;28:847-53.

  17. Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, pharmacodynamics and physiologicallybased pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet. 2013;52:83-124.

  18. Shi S. Biologics: an update and challenge of their pharmacokinetics. Curr Drug Metab. 2014;15:271-90.

  19. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:633-59.

  20. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993;21:735-50.

  21. Zhang L, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodynamics. 2003;30(6):387- 404.

  22. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol. 2002;20(24):4713-21.

  23. Budha NR, Kovar A, Meibohm B. Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects. AAPS journal. 2011;13(4):650-61.

  24. Jolling K, Ruixo JJP, Hemeryck A, Piotrovskij V, Greway T. Population pharmacokinetic analysis of pegylated human erythropoietin in rats. J Pharm Sci. 2004;93(12): 3027-38.

  25. Allon M, Kleinman K, Walczyk M, Kaupke C, Messer-Mann L, Olson K, et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clin Pharmacol Ther. 2002;72(5):546-55.

  26. Woo S, Jusko WJ. Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metabolism and Disposition. 2007;35(9):1672-8.

  27. Ait-Oudhia S, Scherrmann J-M, Krzyzanski W. Simultaneous pharmacokinetics/ pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats. J Pharmacol Exp Ther. 2010a;334(3):897-910.

  28. Locatelli F, Reigner B. CERA: pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease. Expert Opin Investig Drugs. 2007;16(10):1649-61.




2020     |     www.medigraphic.com